Accelerate to discover
Related topics
Cesium-137 versus X-ray irradiation preconditioning in immunodeficient NOG mice
Dec 28, 2020
Radio-active sources have been used routinely for the preconditioning in humanized mouse models, but safety issues have...
EV imaging series: Using ONI super-resolution to characterize single-EVs
Dec 23, 2020
To date, researchers commonly use flow-based characterization methods, fluorescence imaging techniques and electron...
Don’t Let Waste Anesthetic Gases Harm You!
Dec 21, 2020
Many projects have been devoted to the study of the correlation between anesthetics and Alzheimer’s disease....
Advances in Leukemia research using shear flow and Bioflux system
Dec 10, 2020
Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...
Dosimetric characterization of an X-ray irradiator for use with cells
Dec 4, 2020
This study aims to characterize an X-ray irradiator for use with cells using its internal parallel-plate ionization...
Modeling multiple myeloma-Bone Marrow interactions using Synthecon rotating-wall vessels
Dec 2, 2020
Multiple myeloma develops primarily inside the bone marrow microenvironment, that confers pro-survival signals and drug...
Bruker webinar: Ear evolution in fossil mammals
Nov 27, 2020
Hearing is just one of the functions aside of providing balance. Even juveniles obtain a fully developed ear region...
ONI Nanoimager joins the fight against COVID-19
Nov 24, 2020
ONI is supporting the global effort into research and diagnostics to tackle the COVID-19 pandemic. ONI is currently...
May 15, 2019
Identification of structural variants (SVs) is critical to the prognosis of acute myeloid leukemia (AML) and other hematologic malignancies. SVs are not readily identified by next generation sequencing methods and are currently diagnosed by cytogenetics, an intrinsically low resolution tool. Dr. James Broach from Penn State Hershey will discuss a new method for determining large SVs as a clinical tool for evaluating AML and other cancer genomes using Bionano optical mapping. Dr. Broach has applied this technology for detection of SVs in a variety of cancer cell lines and directly from leukemia patient blood samples. In all cases, they have identified all the SVs reported by classic cytogenetic analysis and, in addition, a large number of translocations, deletions and insertions not observed by cytogenetics.
Related technologies: Genome mapping
Get more info
Brand profile
A revolutionary NanoChannel technology for Genome mapping of extremely long DNA without amplification, providing long-range contiguity and eliminating PCR bias.
More info at:
www.bionanogenomics.com
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
BioTech a.s. © 2014
Designed & developed by imagineit
Technologies
